

1641  
JW


PTO/SB/21 (02-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)		Application Number	10/071,844
		Filing Date	February 8, 2002
		First Named Inventor	Lawrence M. KAUVAR
		Art Unit	1641
		Examiner Name	G. W. Counts
Total Number of Pages in This Submission	6	Attorney Docket Number	388512010500

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input checked="" type="checkbox"/> Amendment/Reply (5 pages)  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC)  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Return Receipt Postcard
<div>Remarks</div> <p><b>Customer No. 25225</b></p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Kate H. Murashige - 29,959
Signature	<i>Kate H. Murashige</i>
Date	August 17, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: August 17, 2004	Signature: <i>Marian L. Christopher</i> (Marian L. Christopher)



PATENT  
Docket No. 388512010500

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 8-17-04

Signature:

*Marian Christopher*  
(Marian Christopher)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Lawrence M. KAUVAR.

Serial No.: 10/071,844

Filing Date: 8 February 2002

For: REAL TIME DETECTION OF  
INTERMOLECULAR INTERACTION

Examiner: Gary W. Counts

Group Art Unit: 1641

**AMENDMENT UNDER 37 C.F.R. § 1.111**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is in response to an Office Action herein, mailed 6 August 2004, time for response to which was set to expire 6 September 2004. Restriction was required among four groups. Applicants hereby elect to prosecute the claims of Group I, claims 1-11, drawn to a method to determine whether a first substance interacts with a second substance. This election is made without traverse with respect to Groups III and IV but with traverse with respect to Group II.

It is difficult to see how examination of Groups I and II together would place any kind of undue burden, or any burden at all, on the Office. Clearly if claims 1-11 are novel and inventive, where an assay is claimed, no further invention is required to use that method as a screening tool. Accordingly, reconsideration of the Restriction requirement as it applies to Groups I and II is respectfully requested.

Applicants will cancel the claims of Groups III and IV in response to this Office action.